^Bartoszyk GD, van Amsterdam C, Böttcher H, Seyfried CA (July 2003). "EMD 281014, a new selective serotonin 5-HT2A receptor antagonist". European Journal of Pharmacology. 473 (2–3): 229–30.
doi:
10.1016/S0014-2999(03)01992-7.
PMID12892843.
^Teegarden BR, Al Shamma H, Xiong Y (2008). "5-HT(2A) inverse-agonists for the treatment of insomnia". Current Topics in Medicinal Chemistry. 8 (11): 969–76.
doi:
10.2174/156802608784936700.
PMID18673166.
^Monti JM, Jantos H (September 2006). "Effects of activation and blockade of 5-HT2A/2C receptors in the dorsal raphe nucleus on sleep and waking in the rat". Progress in Neuro-psychopharmacology & Biological Psychiatry. 30 (7): 1189–95.
doi:
10.1016/j.pnpbp.2006.02.013.
PMID16713054.
S2CID12837755.
^Monti JM, Jantos H (December 2006). "Effects of the serotonin 5-HT2A/2C receptor agonist DOI and of the selective 5-HT2A or 5-HT2C receptor antagonists EMD 281014 and SB-243213, respectively, on sleep and waking in the rat". European Journal of Pharmacology. 553 (1–3): 163–70.
doi:
10.1016/j.ejphar.2006.09.027.
PMID17059817.
^Patel JG, Bartoszyk GD, Edwards E, Ashby CR (April 2004). "The highly selective 5-hydroxytryptamine (5-HT)2A receptor antagonist, EMD 281014, significantly increases swimming and decreases immobility in male congenital learned helpless rats in the forced swim test". Synapse. 52 (1): 73–5.
doi:
10.1002/syn.10308.
PMID14755634.
S2CID21941333.
^Adamec R, Creamer K, Bartoszyk GD, Burton P (November 2004). "Prophylactic and therapeutic effects of acute systemic injections of EMD 281014, a selective serotonin 2A receptor antagonist on anxiety induced by predator stress in rats". European Journal of Pharmacology. 504 (1–2): 79–96.
doi:
10.1016/j.ejphar.2004.09.017.
PMID15507224.
^Bartoszyk GD, van Amsterdam C, Böttcher H, Seyfried CA (July 2003). "EMD 281014, a new selective serotonin 5-HT2A receptor antagonist". European Journal of Pharmacology. 473 (2–3): 229–30.
doi:
10.1016/S0014-2999(03)01992-7.
PMID12892843.
^Teegarden BR, Al Shamma H, Xiong Y (2008). "5-HT(2A) inverse-agonists for the treatment of insomnia". Current Topics in Medicinal Chemistry. 8 (11): 969–76.
doi:
10.2174/156802608784936700.
PMID18673166.
^Monti JM, Jantos H (September 2006). "Effects of activation and blockade of 5-HT2A/2C receptors in the dorsal raphe nucleus on sleep and waking in the rat". Progress in Neuro-psychopharmacology & Biological Psychiatry. 30 (7): 1189–95.
doi:
10.1016/j.pnpbp.2006.02.013.
PMID16713054.
S2CID12837755.
^Monti JM, Jantos H (December 2006). "Effects of the serotonin 5-HT2A/2C receptor agonist DOI and of the selective 5-HT2A or 5-HT2C receptor antagonists EMD 281014 and SB-243213, respectively, on sleep and waking in the rat". European Journal of Pharmacology. 553 (1–3): 163–70.
doi:
10.1016/j.ejphar.2006.09.027.
PMID17059817.
^Patel JG, Bartoszyk GD, Edwards E, Ashby CR (April 2004). "The highly selective 5-hydroxytryptamine (5-HT)2A receptor antagonist, EMD 281014, significantly increases swimming and decreases immobility in male congenital learned helpless rats in the forced swim test". Synapse. 52 (1): 73–5.
doi:
10.1002/syn.10308.
PMID14755634.
S2CID21941333.
^Adamec R, Creamer K, Bartoszyk GD, Burton P (November 2004). "Prophylactic and therapeutic effects of acute systemic injections of EMD 281014, a selective serotonin 2A receptor antagonist on anxiety induced by predator stress in rats". European Journal of Pharmacology. 504 (1–2): 79–96.
doi:
10.1016/j.ejphar.2004.09.017.
PMID15507224.